The neonatal crystallizable fragment receptor (FcRn) is responsible for maintaining the long half-life and high levels of the two most abundant circulating proteins, albumin and IgG. In the latter case, the protective mechanism derives from FcRn binding to IgG in the weakly acidic environment contained within endosomes of hematopoietic and parenchymal cells, whereupon IgG is diverted from degradation in lysosomes and is recycled. The cellular location and mechanism by which FcRn protects albumin are partially understood. Here we demonstrate that mice with global or liver-specific FcRn deletion exhibit hypoalbuminemia, albumin loss into the bile, and increased albumin levels in the hepatocyte. In vitro models with polarized cells illustrate that FcRn mediates basal recycling and bidirectional transcytosis of albumin and uniquely determines the physiologic release of newly synthesized albumin into the basal milieu. These properties allow hepatic FcRn to mediate albumin delivery and maintenance in the circulation, but they also enhance sensitivity to the albumin-bound hepatotoxin, acetaminophen (APAP). As such, global or liver-specific deletion of FcRn results in resistance to APAP-induced liver injury through increased albumin loss into the bile and increased intracellular albumin scavenging of reactive oxygen species. Further, protection from injury is achieved by pharmacologic blockade of FcRn-albumin interactions with monoclonal antibodies or peptide mimetics, which cause hypoalbuminemia, biliary loss of albumin, and increased intracellular accumulation of albumin in the hepatocyte. Together, these studies demonstrate that the main function of hepatic FcRn is to direct albumin into the circulation, thereby also increasing hepatocyte sensitivity to toxicity.
The neonatal crystallizable fragment receptor (FcRn) is responsible for maintaining the long half-life and high levels of the two most abundant circulating proteins, albumin and IgG. In the latter case, the protective mechanism derives from FcRn binding to IgG in the weakly acidic environment contained within endosomes of hematopoietic and parenchymal cells, whereupon IgG is diverted from degradation in lysosomes and is recycled. The cellular location and mechanism by which FcRn protects albumin are partially understood. Here we demonstrate that mice with global or liver-specific FcRn deletion exhibit hypoalbuminemia, albumin loss into the bile, and increased albumin levels in the hepatocyte. In vitro models with polarized cells illustrate that FcRn mediates basal recycling and bidirectional transcytosis of albumin and uniquely determines the physiologic release of newly synthesized albumin into the basal milieu. These properties allow hepatic FcRn to mediate albumin delivery and maintenance in the circulation, but they also enhance sensitivity to the albumin-bound hepatotoxin, acetaminophen (APAP). As such, global or liver-specific deletion of FcRn results in resistance to APAP-induced liver injury through increased albumin loss into the bile and increased intracellular albumin scavenging of reactive oxygen species. Further, protection from injury is achieved by pharmacologic blockade of FcRn-albumin interactions with monoclonal antibodies or peptide mimetics, which cause hypoalbuminemia, biliary loss of albumin, and increased intracellular accumulation of albumin in the hepatocyte. Together, these studies demonstrate that the main function of hepatic FcRn is to direct albumin into the circulation, thereby also increasing hepatocyte sensitivity to toxicity.
FcRn | albumin | liver | bile | toxin A lbumin and IgG are the most long-lived and abundant circulating serum proteins. Their persistence is regulated by the neonatal crystallizable fragment receptor (FcRn), which binds both proteins in a pH-dependent manner, favoring interactions within intracellular organelles such as the endosome (1) (2) (3) . In the case of monomeric IgG, binding to FcRn in acidic endosomes of endothelial and hematopoietic cells serves to recycle IgG to the cell surface where it is released into the circulation at physiologic pH (4, 5) . In a similar manner, FcRn also mediates the bidirectional transport of IgG across a variety of polarized epithelial cells (6) (7) (8) (9) . This knowledge has led to therapeutic innovations that aim either to recombine biologic agents with the Fc fragment of IgG to enable FcRn interactions, thus prolonging the half-life of the therapeutic, or conversely to reduce the therapeutic agent's half-life by disabling binding to FcRn (10) .
Less is known about the physiologic mechanisms that underlie albumin homeostasis through interactions with FcRn and what cell types are involved. Although albumin and IgG display pHdependent binding to FcRn, the interaction surface, affinity, and mode of interaction differ between the two proteins (11) (12) (13) . Still,
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because the half-life and the steady-state concentration of albumin are decreased in FcRn-deficient individuals and animals, it was proposed that FcRn diverts not only IgG but also albumin from intracellular degradation, prolonging the life spans of both proteins (3, 11, 14, 15) . Further, both the conditional deletion of FcRn in endothelial and hematopoietic cells and renal deficiency of FcRn have been shown to cause hypoalbuminemia (16) (17) (18) . In the latter case, the hypoalbuminemia is associated with albuminuria, as is consistent with FcRn's recently identified role in retrieving albumin from the urinary stream to prevent its loss (17) (18) (19) .
Albumin synthesis takes place in the hepatocyte. This specialized parenchymal cell is also a major cellular site for the expression of FcRn, which is distributed intracellularly and localized to the canalicular (apical) and sinusoidal (basal) membranes (20) (21) (22) (23) . However, the functional role played by FcRn in hepatocytes and its consequences for the fate of albumin are unknown. Here we show that FcRn in hepatocytes is critical for directing albumin into the vascular space and away from the bile, thereby also influencing liver susceptibility to injury by toxins capable of binding to albumin.
Results
Hepatic FcRn Deficiency Causes Hypoalbuminemia and Albumin Loss into Bile. We first examined the endogenous levels of albumin in the bloodstream and bile of WT (Fcgrt +/+ ), FcRn-heterozygous (Fcgrt +/− ), and FcRn-deficient (Fcgrt −/− ) mice. Consistent with prior published results (1, 3), we observed a significant decrease in the serum levels of albumin (Fig. 1A) and IgG (Fig. 1B) in Fcgrt −/− mice compared with Fcgrt +/+ and Fcgrt +/− mice (Table 1) . In contrast, the levels of albumin (Fig. 1A) and IgG (Fig. 1B) (24, 25) , a minor subset of cells in the liver whose expression of FcRn has not been described (23, 26) . Alb Cre Fcgrt fl/fl mice exhibited a significant decrease in serum albumin together with increased albumin loss into the bile (Fig. 1C) that was proportional to the levels observed in the serum and bile of Fcgrt −/− mice totally lacking FcRn expression (Fig. 1A) . The observed increase in bile albumin was not caused by a nonspecific increase in the permeability of the liver, because no differences in the levels of FITC-labeled dextran, with a molecular weight equivalent to albumin, were observed in the bile of Fcgrt −/− mice or WT mice 24 h after i.v. injection (Fig. S1B) . In comparison, liver-specific deletion of Fcgrt did not cause hypogammaglobulinemia and caused only a trend toward increased levels of IgG in the bile (Fig. 1D) Cre Fcgrt fl/fl mice"), did not affect circulating or bile albumin levels (Fig. 1E) or bile IgG levels, although it did result in hypogammaglobulinemia (Fig. 1F) . Thus, liver cells, most likely hepatocytes, and cells of the hematopoietic system play analogous, nonredundant roles in maintaining albumin and IgG levels, respectively, in the circulation, and the absence of FcRn expression in the liver causes significant albumin loss into the bile without changes in serum IgG levels.
FcRn Regulates Albumin Recycling, Transport, and the Vectoral Accumulation of Albumin in Polarized Epithelia. We next sought to understand the mechanisms by which hepatic FcRn maintains albumin in the circulation and prevents its loss into the bile. In the absence of a well-validated polarized hepatocyte-derived cell line, we first investigated the ability of Madin-Darby canine kidney II (MDCK II) cells transfected with either human FcRn (hFcRn) and human β 2 m (hβ 2 m) or rat FcRn (rFcRn) and rat β 2 m (rβ 2 m), or with only their respective β 2 m (vector) as control, to transcytose albumin. These cells polarize efficiently on transwell inserts and have been used previously to model the transcytosis of IgG (8, 9, 27, 28) . Indeed, hFcRn/hβ 2 m, but not vector control cells, were able to transport human ( Fig. 2A ) and rat albumin (Fig. 2B ) in apical-to-basal (A→B) and basal-to-apical (B→A) fashion, consistent Cre ) (n = 6-7; ***P < 0.001). Data were statistically analyzed by two-way ANOVA with Fisher's LSD post hoc test ( Fig. 2 A-F) . Open circles represent biological replicates. with a bidirectional mechanism of transcytosis and the differential ability of hFcRn to bind to different albumin orthologs (11) . In that respect, heterogeneity in the binding of FcRn orthologs to albumin orthologs has been observed. In particular, hFcRn has been shown to possess higher affinity to mouse and rat albumin than to the human ortholog, as determined by surface plasmon resonance (SPR) analyses. In addition, both mFcRn and rFcRn exhibit weak binding to human albumin compared with their strong binding to the mouse and rat albumin orthologs (11) . Similarly, rFcRn/rβ 2 mtransfected MDCK II cells, but not vector control cells, exhibited bidirectional transcytosis of rat albumin (Fig. 2B ), illustrating that human and rodent FcRn are capable of mediating the bidirectional transcytosis of albumin in a polarized epithelial cell model. We next assessed whether polarized MDCK II cells were able to recycle albumin in the presence or absence of hFcRn/hβ 2 m. Notably, human albumin was recycled efficiently at the basal surface of hFcRn/hβ 2 m-expressing MDCK II cells in a dose-dependent manner but not by vector control or, as another negative control, by rFcRn/rβ 2 m-expressing MDCK II cells (because rFcRn binds weakly to human albumin, as explained above) (Fig. 2C) (29, 30) . Furthermore, as is consistent with defective albumin trafficking and increased leakage into the bile in the absence of FcRn in vivo, when rat albumin was injected into WT or Fcgrt −/− mice and was measured 24 h later, rat albumin levels were significantly higher in bile and lower in serum from FcRn-deficient animals than in serum from WT controls (Fig. 2D) . Thus, exogenous rat albumin was lost more readily in the bile in the absence of FcRn.
To understand the consequences of FcRn coexpression in cells actively producing albumin, we examined the ability of FcRn to control the net accumulation of newly synthesized albumin on either side of a polarized epithelial surface. To do so, MDCK II cells expressing hβ 2 m alone (vector control) or expressing hFcRn/ hβ 2 m were transfected with human albumin, and the rates of newly synthesized albumin accrued as apical and basal secretions were monitored over time. MDCK II cells expressing human albumin with hβ 2 m released significantly higher concentrations of albumin in the apical chamber (modeling the canalicular surface of a hepatocyte) than in the basolateral chamber (modeling the sinusoidal surface of a hepatocyte) at all time points analyzed (Fig. 2E ). This trend was reversed in MDCK II cells coexpressing hFcRn together with hβ 2 m and human albumin, for which the predominant direction of albumin accretion was basolateral (Fig. 2F ). These data suggest that FcRn may facilitate the export of albumin in the physiologic direction and that this export is further consolidated through basal recycling and potential apical scavenging of albumin.
We further examined the levels of intracellular albumin in MDCK II cells expressing albumin in the presence (hFcRn/hβ 2 m) or absence (hβ2m alone) of FcRn by flow cytometry and observed an intracellular accumulation of albumin in the absence of hFcRn (Fig. S2A) Fig. 2G and Fig. S2B ) and by intracellular flow cytometry ( Fig. 2H and Fig. S2C ) analysis of hepatocytes purified from perfused livers. Thus, as shown in MDCK cells and primary hepatocytes, newly synthesized albumin accumulates intracellularly in the absence of FcRn.
Taken together, these results suggest that in hepatocytes FcRn first exerts its protective effects on albumin by facilitating the vectorial delivery of albumin in the physiologic basolateral direction. FcRn-mediated albumin protection is further augmented by its basal recycling and, potentially, by the apical scavenging functions implied by the A→B albumin transcytosis that was observed. 
Hepatic FcRn Renders the Liver Susceptible to the Effects of an
Hepatocyte Toxin. In addition to preserving the colloid osmotic pressure, albumin also possesses vital antioxidant properties and is an important carrier protein that binds to and transports numerous elements, nutrients, proteins, and sometimes toxins (31) . In the latter case, albumin-bound toxins might persist longer in the circulation, or albumin binding might decrease toxicity by decreasing free toxin levels. Indeed, one of the most commonly used analgesics, acetaminophen (para-acetylaminophenol, APAP), is known to bind albumin in the circulation (32) and is toxic to the liver at high doses (33, 34) . When ingested in excess (above 10 g/d or 200 mg/kg for humans), the hepatocyte glucuronide pathway is saturated, resulting in the production and accumulation of a toxic byproduct, N-acetyl-p-benzo-quinoneimine (NAPQI) (35) . NAPQI depletes glutathione (GSH) and binds in particular to mitochondrial proteins, mainly to the amino acid cysteine, causing oxidative stress, mitochondrial damage, and ultimately hepatocyte death (34, 36) . We therefore hypothesized that FcRn affects the sensitivity of the liver to toxins, using APAP as a model of liver toxicity.
To examine this question, we took advantage of a previously described humanized mouse strain that expresses hFcRn under the control of human endogenous FcRn promoter as well as hβ 2 m and is deficient in mouse FcRn [B6.Cg-Fcgrt tm1Dcr Tg(FCGRT)32Dcr/ DcrJ mice, hereafter referred to as "FCGRT TG mice"] (1, 7). Immunostaining of liver sections showed that human FcRn was distributed in a vesicular pattern within hepatocytes of FCGRT TG mice similar to that described in other polarized epithelial cell types (8) , with evidence of expression on both the sinusoidal (basal) and canalicular (apical) membranes in hepatocytes, as predicted by previous studies (Fig. S3A) (21) (22) (23) . As is consistent with the ability of hFcRn to bind to mouse albumin (29) (Fig. 3B) . Importantly, this protection was associated with increased excretion of APAP into the bile over time as determined via bile duct cannulation (Fig. 3C ) and with decreased levels of APAP in the serum of Fcgrt −/− mice ( Fig. 3D ) relative to WT and FCGRT TG controls. We also found evidence for APAP in association with albumin in the bile of Fcgrt −/− mice exposed to APAP ( Fig. S3 B and D) . In SPR experiments, neither APAP nor NAPQI binding to albumin interfered with albumin's ability to bind to FcRn, in contrast to the long-chain fatty acid C18, oleate, which binds albumin and blocks its interaction with FcRn ( Fig. S3E) (37) . These changes in APAP levels in the bile and serum were associated with significantly lower serum alanine aminotransferase (ALT) levels in Fcgrt −/− mice than in WT or FCGRT TG mice 8 h after sublethal APAP administration (400 mg/kg) (Fig. 3E ).
To determine whether FcRn expression by hepatocytes contributes to the sensitivity of the liver to APAP-associated hepatotoxicity, we administered a lethal dose of APAP to Alb ). Alb Cre Fcgrt fl/fl mice exhibited superior survival after lethal APAP administration (600 mg/kg) (Fig. 3F) , as did Fcgrt −/− mice (Fig. 3B) . Additionally, mice with liver-specific deletion of FcRn displayed significantly decreased circulating ALT (Fig. 3G ) and serum APAP levels ( Fig. 3H ) 8 h after sublethal APAP (400 mg/kg) administration. Consequently, FcRndeficient hepatocytes are protected from APAP-induced toxicity in association with decreased serum levels of APAP.
We hypothesized that the protection from APAP-mediated hepatotoxicity in FcRn-deficient mice is dependent on either the loss of albumin into the bile, resulting in the removal of APAP and its metabolites as described above, and/or on the accumulation of albumin in the hepatocyte, where it serves as an antioxidant through the unpaired cysteine 34 residue in humans and mice and potentially cysteine 579 in mice (38) . To investigate whether FcRn influences the antioxidant buffering capacity of albumin, we measured reactive oxygen species (ROS) content using 2′,7′-dichlorodihydrofluorescein diacetate (DCFH-DA) staining in Fcgrt −/− and Fcgrt +/+ hepatocytes after exposure to hydrogen peroxide (H 2 O 2 ) . As is consistent with the elevated intracellular levels of albumin observed in the absence of FcRn (Fig. 2 G and H and Fig. S2 ), we observed lower levels of ROS in primary Fcgrt −/− hepatocytes than in Fcgrt +/+ hepatocytes (Fig. 3I) . Therefore, the loss of FcRn in hepatocytes results in albumin retention, which correlates with greater antioxidant buffering capacity.
To confirm these results, we assessed ROS production upon H 2 O 2 or APAP treatment in MDCK II cells expressing human albumin in the presence or absence of hFcRn/hβ 2 m; these cells accumulate albumin in the absence of functional FcRn (Fig. S2A) . MDCK II cells expressing hβ 2 m/human albumin were more resistant to H 2 O 2 and APAP treatment and generated lower amounts of ROS than cells expressing hβ 2 m alone (vector), cells expressing hβ 2 m/hFcRn, or cells coexpressing hβ 2 m/hFcRn and human albumin (Fig. S3 F and G) . This finding was reflected further in the greater survival of hβ 2 m/human albumin-positive MDCK II cells upon identical H 2 O 2 treatment (Fig. S3H) .
To validate further the central role of albumin in FcRn-dependent protection from APAP toxicity, we assessed the response of albumindeficient (Alb ) mice 8 h after APAP administration (Fig. 3J) . Thus, these studies show that APAP protection depends on the transporting and antioxidant activities of albumin. mice. Given that FCGRT TG mice were as susceptible as WT mice to APAP hepatotoxicity, we focused our attention on this humanized model to permit the application of human FcRn-specific agents. To do so, we used a previously described mouse anti-human FcRn monoclonal antibody, ADM31, which binds in the nanomolar range at both pH 7.4 and pH 6.0 and specifically blocks the interaction site for albumin but not for IgG (39, 40) . In the in vitro studies with MDCK II cells expressing hFcRn/hβ 2 m, pretreatment with ADM31, but not with an IgG2b isotype control, inhibited the transcytosis of human albumin (Fig. 4A) . Furthermore, we observed significant hypoalbuminemia as well as albumin loss into the bile (Fig. S4A) 16 h after i.v. administration of ADM31 to naive FCGRT TG mice as compared with untreated or IgG2b isotype-treated control mice. In vitro treatment of primary hepatocytes from FCGRT TG mice with ADM31, but not with the isotype control, also resulted in hepatocyte accumulation of albumin ( Fig. S4 B and C) . As shown in Fig. 4B , ADM31 treatment 16 h before lethal APAP administration also significantly improved the survival of FCGRT TG mice to a level similar to that observed in Fcgrt −/− mice and significantly longer than seen for untreated FCGRT TG mice or FCGRT TG mice treated with the IgG2b isotype. In addition, pretreatment with ADM31, but not with the isotype control, resulted in significantly decreased serum ALT levels in the circulation 8 h after sublethal APAP administration (Fig. 4C ) and decreased levels of phosphorylated JNK (p-JNK) in liver tissues at 2 h after APAP administration (Fig. S4 D and E) . JNK phosphorylation actively regulates NAPQI-induced mitochondrial GSH depletion, dysfunction, and hepatocyte death (41) . Histological analysis of H&E-stained liver sections confirmed a significant reduction in necrotic areas in ADM31-treated mice in this preventative model (Fig. 4 D and E) . Moreover, the protection afforded by albumin-FcRn blockade with the ADM31 monoclonal antibody in the context of APAP administration was associated with decreased albumin in the circulation (Fig. S4F) and increased biliary albumin loss (Fig. S4G) .
A Peptide Mimetic Can Disrupt Human FcRn-Albumin Interactions and Provide Protection Against APAP-Induced Hepatotoxicity. To substantiate our findings, we sought a different approach relying on a previously described phage-display library (42) to identify a heptadecamer (17-mer) peptide, SYN1753 (Ac-RYFCTKWKHGWCEEVGT-CONH 2 ), capable of binding to soluble hFcRn (shFcRn) and specifically inhibiting its interaction with albumin (Table 2) . We confirmed the specificity of the SYN1753 for the albumin-binding site on hFcRn by solving the X-ray cocrystal structure of the complex [Protein Data Bank (PDB) ID code: 5BJT] (Fig. 4 F-H and Table S1 ). This complex consisted of a pair of SYN1753 peptides forming contacts with a single hFcRn molecule (Fig. 4F) at a location that defined specific albumin-binding epitopes. These sites were centered on several previously identified albumin contact residues in FcRn, Phe157 (F157), His161 (H161), and His166 (H166) (Fig. 4 G and H) , and provide evidence for the bona-fide nature of this FcRn-albuminbinding mimic (12, 43) . Furthermore, comparison of the FcRn: (SYN1753) 2 complex with previously published FcRn-albumin crystallographic studies (37) showed that the pair of SYN1753 peptides bind hFcRn at the same binding site as domain I of albumin (Fig. 4I) . The N and C termini of the two SYN1753 peptides were in close proximity to each other in the X-ray crystal structure (Fig. 4G ), suggesting that a covalently linked dimer may represent a more optimized peptide. We therefore generated the 37-aa dimeric peptide SYN3258 by fusing two SYN1753 peptides with a flexible glycine linker [Ac-(SYN1753)-GGG-(SYN1753)-CONH 2 ]. Both parental monomeric (SYN1753) and dimeric (SYN3258) peptides were able to inhibit FcRn-directed transcytosis of albumin in MDCK II cells relative to that observed with a scrambled control peptide (Fig. S4H) . When continuously administered at a dose of 40 mg/kg body weight per day via an i.p. pump, SYN3258, but not a control peptide, not only protected the liver from injury after lethal APAP administration (Fig. 4J ) but also improved mouse survival (Fig. S4I) . As expected, SYN3258 treatment also led to significant hypoalbuminemia and increased albumin loss into the bile (Fig. S4J ). These studies with a peptide mimetic confirm that disrupting albumin interactions with hFcRn protects the liver from the toxic effects of APAP.
Antibody-Mediated Protection Against APAP-Induced Hepatotoxicity Through Disruption of Human FcRn-Albumin Interactions Can Be
Extended to a Therapeutic Setting. Having shown that albuminFcRn blockade before APAP administration prevents hepatotoxicity, we examined the ability of albumin-FcRn blockade to protect the liver in a therapeutic rather than preventative model. To do so, we administered the ADM31 monoclonal antibody 2 h after lethal exposure to APAP (Fig. S5A) . As shown in Fig. S5B , therapeutic administration of ADM31 after lethal APAP treatment improved, although nonsignificantly, the survival of FCGRT TG mice compared with untreated mice or mice treated with the IgG2b isotype.
In a separate experimental cohort with sublethal APAP administration (400 mg/kg), we further compared the effectiveness of albumin-FcRn blockade to treatment with the standard clinical antidote, N-acetylcysteine (NAC), which reduces APAP toxicity by replenishing liver stores of the antioxidant GSH (44) , and observed that ADM31 was equally as effective as NAC in reducing circulating ALT levels in FCGRT TG mice in contrast to mice treated with the IgG2b isotope (Fig. 5A) . Finally, to provide further relevance to human treatment, we developed a humanized, affinity-matured version of ADM31. The resulting antibody (SYNT002-08) is a humanized, affinity-matured IgG4-κ monoclonal antibody containing a CH 3 C-terminal lysine deletion (ΔK478) and a serine-to-proline (S241P) mutation that stabilizes the hinge region in vivo (45) . SYNT002-08 exhibited 10-fold improved binding to shFcRn compared with the parental ADM31, with a K d of 4.0 nM at pH 7.4 and 0.6 nM at pH 6.0 (Fig. S5 C and D Tg(FCGRT)32Dcr/MvwJ (46)], it effectively increased albumin catabolism in a dose-dependent manner (Fig. S5E) . Following the therapeutic protocol described above (Fig. S5A) , serum ALT levels showed that SYNT002-08 at a dose of 10 mg/kg provided protection to FCGRT TG mice equivalent to that provided by NAC administered 2 h after sublethal APAP challenge when compared with control treatment (with PBS or the IgG4 isotype) (Fig. 5B) . Therefore, in a therapeutic setting, both ADM31 and SYNT002-08 antibodies that block the albumin-hFcRn interaction confer protection from toxic APAP exposure to the same extent as NAC.
Discussion
The importance of FcRn in sustaining high serum concentrations of circulating albumin is well established in both humans and mice (3, 14, 15) . However, the cellular sites and the underlying mechanisms by which FcRn performs this critical function are poorly understood. The possibility that endothelial cells support albumin homeostasis through their expression of FcRn is supported by studies of Ward and colleagues using Tie2 Cre-mediated conditional Fcgrt deletion (16) . Other studies have documented the involvement of renal tubular epithelial cells in albumin homeostasis (17) (18) (19) . Here, we have demonstrated that parenchymal cells in the liver, mainly hepatocytes that are the source of serum albumin, require FcRn to deliver and maintain sufficient amounts of albumin in the circulation. Accordingly, the absence of FcRn in the liver results in hypoalbuminemia, the accumulation of intracellular albumin in hepatocytes, and a protein-losing biliopathy caused by loss of albumin into the bile. This effect is selective to albumin homeostasis, in that liver deficiency in FcRn does not lead to hypogammaglobulinemia or appreciable leakage of IgG into the bile. These studies uncover attributes of both hepatocytes and FcRn in ensuring the systemic functions of albumin.
In the Alb Cre animal model, the cholangiocyte, another liver cell type, has also been shown to possess Cre-recombinase activity, so this cell type must be considered in the phenotype observed in Alb
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Fcgrt
fl/fl mice (47, 48) . Cholangiocytes account for ∼5% of the liver cell population, line the bile ducts, and modify bile through processes of secretion or absorption (49) . Although FcRn expression in cholangiocytes has not been reported, FcRn in these cells might possess a role similar to that described in proximal tubular epithelial cells of the kidney, where it has been shown to serve in albumin reabsorption from the urine (17) . If expressed, FcRn in cholangiocytes could assist in the albumin-reuptake process to minimize albumin loss into the bile. Thus, the high albumin biliary loss described in Fcgrt −/− or Alb Cre Fcgrt fl/fl mice might stem from FcRn dysfunction not only in hepatocytes but conceivably also in cholangiocytes, making studies of FcRn function in cholangiocytes and its role in albumin homeostasis and susceptibility to liver toxins of great interest in future studies. Nonetheless, because we observed significant hepatocyte injury using an hepatocyte-specific toxin, as defined by histopathology and the presence of elevated circulating hepatocyte-derived enzymes after APAP administration, as well as an increase in albumin content in primary hepatocytes in Fcgrt −/− or Alb Cre Fcgrt fl/fl mice, it is likely that the main cell type contributing to the observations described is the hepatocyte. Mechanistically, our studies point to several different means by which FcRn in the hepatocyte, the site of albumin synthesis, contributes to the accumulation of albumin and its maintenance in the circulation. Similar to the endothelium (16) and proximal tubular epithelial cells of the renal collecting system (17) (18) (19) , our studies suggest that FcRn in the hepatocyte basally recycles and apically scavenges albumin. This activity is supported by our results demonstrating basolateral recycling and A→B transcytosis in polarized MDCK II cells. We also observe that newly synthesized albumin accumulates apically in the absence of FcRn and accrues basally only if FcRn is expressed. These processes suggest that FcRn controls albumin homeostasis by determining the vectorial delivery of albumin to the basal surface through a combination of apical scavenging, basal recycling, and potentially facilitating albumin secretion at its site of production. Our finding of increased albumin content in the liver in the absence of FcRn thus may be a consequence of multiple factors. These include diminished vectorial delivery of albumin to the basal surface and its recycling in this location. In addition, compensatory mechanisms are engaged whereby hepatocyte biosynthesis is up-regulated, including albumin, to normalize the levels of circulating proteins, as suggested by Anderson and colleagues (20) . Thus, a major function of FcRn at the site of albumin synthesis is to guide albumin into the circulation, salvage it from the canalicular compartment, and direct its delivery to the vasculature.
Significantly, we also find that these cell-intrinsic functions of FcRn render the hepatocyte susceptible to injury when exposed to certain hepatotoxins, especially those capable of albumin binding and targeting the hepatocyte. This hepatocellular sensitivity thus stems from FcRn's role in directing albumin into the circulation and away from the hepatocyte or bile and proceeds via mechanisms derived from both its carrier and antioxidant functions. In the first case, the maintenance of albumin in the circulation by hepatic FcRn may potentially prolong host exposure to a toxin when the toxin is able to bind albumin. Thus, when FcRn is genetically deleted, including conditional deletion in the liver, or when FcRn interactions with albumin are specifically blocked with monoclonal antibodies or peptidomimetics, the liver may be protected to some degree from exposure to APAP and the accompanying liver injury through the decreased albumin (and toxin) in the circulation and their increased loss in the bile.
There are some limitations to this proposed albumin-FcRndependent mechanism of protection that require additional experimentation in the future. For instance, it is generally acknowledged that only a limited quantity of APAP is bound to serum albumin. At normal therapeutic doses, less than 10% of APAP is bound by albumin, whereas at elevated, toxic doses the binding is 20-25% (50, 51) . This low APAP carrying capacity of albumin suggests either that the flux of APAP-associated albumin is quite large or that other mechanisms are also operative. The latter possibility is likely, in view of the protection observed in therapeutic protocols wherein albumin-FcRn blockade is initiated after APAP exposure, at a time when significant APAP metabolism has already occurred (52) . In accordance with human and mouse studies in which hypoalbuminemia results in an increased rate of albumin synthesis (20, 53) , we detected greater intracellular albumin content in FcRn-deficient hepatocytes and upon antibody-mediated albumin-FcRn blockade. Given the antioxidant capacities of albumin, its accumulation thus can potentially provide additional buffering capacities against oxidative stress and mitochondrial injury during APAP overdose, which involves JNK-dependent, ROS-mediated injury (41) . Indeed, FcRn-deficient and albumin-sufficient hepatocytes as well as albumin-expressing MDCK II cells were less susceptible to H 2 O 2 -or APAP-induced ROS production and the resultant death. Our studies thus suggest that the antioxidant properties of albumin are a potentially additional critical mechanism by which FcRn deficiency or blockade is protective against APAP toxicity. The relative contributions of intracellular albumin accumulation and increased ROS buffering or excretion through reversal of albumin flux into the bile and the clearance of toxic compound to the protection observed with FcRn loss or blockade remain to be elucidated in future studies. Nonetheless, both mechanisms are supported by the increased susceptibility that Alb −/− mice exhibit in response to APAP exposure.
Most of the current albumin-based therapies aim to imitate albumin-FcRn interactions to prolong the circulating half-life of (n = 4-15 from three pooled experiments; *P < 0.05; **P < 0.01). (B) Serum ALT levels 6 and 8 h after APAP administration (400 mg/kg) in FCGRT TG mice that received PBS, NAC (140 mg/kg), SYNT002-8, or IgG4 isotype control (10 mg/kg) 2 h after APAP administration (n = 3-5; *P < 0.05; **P < 0.0038; ***P < 0.001). Data were statistically analyzed by one-way ANOVA (A) or two-way ANOVA with Fisher's LSD post hoc test (B). IQR, interquartile range; U/L, units per liter.
biologics, not to promote their degradation (40) . This promotion of degradation raises the question whether inducing albumin deficiency through pharmacologic blockade would be beneficial. An accumulating body of evidence illustrates a potential detrimental effect of hypoalbuminemia on health (53, 54) . At present, no individuals with FcRn-specific deficiency have been described. Mutations in the B2M gene resulting in the absence of β 2 m expression, which affect MHC class I molecule expression in general and FcRn in particular, have been reported. These individuals, besides being immunodeficient, are characterized by reduced circulating levels of albumin (14, 15) . However, given the broad effects of β 2 m deficiency on immune function, extrapolations from these human subjects is impossible. Still, analbuminemic individuals, although extremely rare, have been described and are mostly asymptomatic with a normal life expectancy (55) . Comparable to analbuminemic humans, albumin-deficient mice, even in the presence of hyperlipidemia, are generally healthy and breed normally (46) . Similarly, FcRn-deficient mice are hypoalbuminemic, but they remain healthy throughout their life. Interestingly, a gradual increase in plasma albumin levels with age is observed in FcRndeficient mice, consistent with a compensatory increase in the rate of hepatic albumin biosynthesis (56) . In light of the absence of serious detrimental symptoms in analbuminemic hosts, given the plethora of important physiological functions carried out by albumin, it is likely that a compensatory increase in the production of other hepatic proteins and/or other physiologic changes occur in this circumstance.
As such, the evidence from human studies as well as from animal models suggests that persistent decreases or even an absence of circulating albumin is not necessarily detrimental, at least when hepatic synthetic function is intact. The results presented in this study demonstrate that short-term FcRn-albumin blockade significantly affects the biodistribution of albumin and is beneficial in an APAP model of hepatotoxicity. Whether these observations extend to other types of hepatotoxicity and whether long-term FcRn-albumin blockade would cause disadvantageous effects on the host need to be assessed in chronic models. It is of additional interest that, in certain conditions such as diabetes mellitus, posttranslational modifications of albumin are associated with toxicity; in such circumstances albumin elimination may also be desirable (57) (58) (59) . Thus, in particular instances, acute albumin depletion might not be harmful and, as seen here, might prove beneficial, without conferring inordinate additional risk, when albumin is carrying toxic drugs or is modified in a pathological manner.
In summary, our studies show that the hepatocyte, where albumin is synthesized, is critical to effecting FcRn-mediated control of albumin homeostasis. The mechanisms involved likely include those also used by the endothelium and renal collecting tubules (e.g., basal recycling and apical scavenging, respectively), as well as those that are unique to the hepatocyte, such as vectorial control of albumin deposition across the sinusoidal surface. Furthermore, we have shown that these albumin-trafficking properties of FcRn render the liver susceptible to injury when exposed to a hepatocyte-specific toxin that binds albumin. Thus, similar to the potential benefit of blocking IgG-FcRn interactions in the treatment of autoimmune diseases (10) , protection of the liver may be achieved by therapeutic blockade of albumin-FcRn interactions.
Materials and Methods
Vectors and Cells. MDCK II cells expressing rβ 2 m or hβ 2 m and respective FcRn were described previously (27, 28) . The human albumin gene was cloned from HepG2 cells, sequence confirmed, inserted into the pBUD4.1 vector (Invitrogen), and then transfected into MDCK II cells expressing only hβ 2 m or both hβ 2 m and hFcRn. Stable clones were selected by zeocin resistance and ring cloning.
Proteins and Reagents. Human albumin (Abserotec; Sigma), rat albumin (Innovative Research), human IgG (Lampire), and rat IgG (Lampire) were used for in vitro transport and in vivo experiments. APAP, NAC, DCFH-DA, and H 2 O 2 were purchased from Sigma. ADM31 is an IgG2b mouse anti-human FcRn monoclonal antibody (39, 40) . IgG2b isotype control was purchased from BioXCell. The mouse, human, or rat albumin and IgG levels were measured using ELISA method. Mouse (E90-134), human (E80-129), and rat (E110-125) albumin and mouse (E90-131) and human (E80-104) IgG ELISA detection kits were obtained from Bethyl Laboratories. Acetaminophen levels were determined using the Acetaminophen LiquiColor Test (Stanbio). ALT levels were measured using the ALT/SGPT Liqui-UV test (Stanbio). HBSS (Sigma) was adjusted to pH 6 or pH 7.4 using HCl or NaOH. FITC-Dextran-70 (Sigma) was diluted in PBS. The peptide inhibitors SYN1753 and SYN3258 (Biogen Idec) were diluted in PBS. The scrambled peptide used in transcytosis experiments was a 15-aa molecule generated by random rearrangement of SYN1753 sequence. The control peptide used in in vivo experiments contained the dimeric structure of SYN3258 in which three amino acids in each monomer were mutated in the following way: W7A, W11A, and V15A. Anti-human albumin-HRP and anti-mouse albumin-HRP were purchased from Bethyl Laboratories; anti-JNK, anti-p-JNK, anti-GAPDH, anti-β-actin, anti-goat-HRP, anti-mouse-HRP, and anti-sheep-HRP were purchased from Cell Signaling. Rat anti-mouse FcRn antibody was produced and validated in house. Anti-mouse albumin-FITC was purchased from Cedarlane (mCLFAG3140); anti-human-albumin-FITC (IC1455G) was purchased from R&D Systems. Mouse IgG1 and IgG2-FITC isotype controls were purchased from eBioscience.
Animals. All animal experiments were approved by the Institutional Animal Care and Use Committee of Harvard Medical School. Mice were housed in approved specific pathogen-free facilities. WT BALB/cJ (bred in house) and C57BL/6 mice (purchased from Jackson Laboratories) were used. Fcgrt Females were used for all APAP toxicity studies, although mice of both sexes were initially tested and showed equivalent responses.
Transcytosis, Recycling, and Secretion Assays. Albumin transcytosis assays were performed as previously described for IgG (28) . Briefly, MDCK II cells expressing hβ 2 m and hFcRn were grown to confluence on Transwells (Costar) and allowed to polarize over 4 d. Eighteen hours before the transcytosis experiment, the medium was changed to serum-free medium without antibiotics. On the day of the experiment, the Transwells were washed with HBSS (pH 7.4) for 20 min before being placed on a new 12-well plate (Costar). The input chamber contained HBSS (pH 6.0), and the exit chamber contained HBSS (pH 7.4); then pH-adjusted albumin was added to the input chamber. For blocking albumin transcytosis with the peptide inhibitors SYN1753 and SYN3258 or antibodies ADM31 and IgG2b, Transwells were preincubated for 20 min in HBSS (pH 6.0) before the addition of albumin in the continued presence of the peptides or antibodies. After incubation for 2 h at 36°C and 5% (vol/vol) CO 2 , the medium in the opposite chamber was harvested, and the albumin concentration was quantified using ELISA. For the recycling assay, the Transwells were washed with HBSS (pH 7.4) for 5 min before being placed on a new 12-well plate with HBSS (pH 6.0) at both chambers. After equilibration at 37°C and 5% CO 2 , pH-adjusted human albumin was added and allowed to incubate for 1 h. The Transwells then were washed with HBSS (pH 6.0) before being placed in a new 12-well plate with HBSS (pH 7.4) in both chambers. After 1-h incubation, medium was removed from the input chamber, and the albumin concentration was measured by an ELISA method. For the human albumin secretion assay the medium was changed to serum-and antibiotic-free medium on the day of the experiment. Fifty microliters of the medium from both chambers was removed periodically over 24 h, and the human albumin concentration was measured using ELISA with adjustment for volume reduction.
Preparation of Mouse Primary Hepatocytes. Primary mouse hepatocytes were isolated as described (62) . Briefly, mice were anesthetized with an i.p. injection of ketamine (100 mg/kg; Webster Veterinary) plus xylazine (10 mg/kg; Webster Veterinary). The inferior vena cava was exposed, cannulated, and perfused for 5 min with liver-perfusion medium (Invitrogen), followed by a 10-min perfusion with liver-digestion medium (Invitrogen), each having been prewarmed to 37°C. The digested liver was diced in cold hepatocyte wash medium (Invitrogen), passed through a 100-μm strainer (Thermo Fisher Scientific), and washed three times. Bile Collection. To remove the bile from the gallbladder, mice were fasted for 4 h before being killed, and immediate laparotomy was performed to expose the gallbladder. A 30-gauge needle was inserted into the gallbladder to aspirate the bile. To remove bile by bile duct cannulation, mice were anesthetized throughout the laparotomy. An abdominal midline incision allowed the gallbladder and biliary tree to be exposed. The cystic duct was ligated with a suture. A small incision was made at the common bile duct before insertion of a PE-10 catheter (Terumo). Bile then was collected at 20-min intervals.
In Vivo Acetaminophen Experiments. For lethal acetaminophen administration, APAP was diluted in warm PBS at a concentration of 33.3 mg/mL. An acetaminophen dose of 600-700 mg/kg body weight administered i.p. was found to be lethal, as titrated in dose-findings experiments, and a dose of 600 mg/kg was used thereafter in all lethal experiments. For sublethal APAP injections, APAP was diluted in warm PBS to a concentration of 25 mg/mL, and a dose of 300-450 mg/kg was administered i.p. to mice. Animals were killed 2, 4, or 8 h after APAP administration; blood was collected via cardiac puncture, and bile was collected as described above. Livers subsequently were collected directly, formalin-fixed, paraffin-embedded, sectioned, and stained with H&E as previously described (63) or were perfused with cold PBS via the inferior vena cava and snap-frozen in liquid nitrogen for later protein analysis by Western blotting as previously described (64) . All mice were fasted 4 h before being killed. For preventive antibody treatment, ADM31 or IgG2b isotype control (30 mg/kg) was administered via the tail vein 16 h before APAP administration. For therapeutic antibody treatment, ADM31 or IgG2b (30 mg/kg) and SYNT002-08 or IgG4 (10 mg/kg) were administered via the tail vein 2 h after APAP treatment. To block the interaction between FcRn and albumin, a cyclic control peptide for SYN3258 was designed in which three key residues per monomer that has been identified by alanine screening to be critical for binding between FcRn and albumin were mutated to alanines (W7A, W11A, V15A). SYN3258 or the control peptide then was administered continuously via an i.p. osmotic pump (ALZET) over a 72-h period. Before the surgical implantation of the pump, mice were anesthetized with Buprenex (0.1 mg/kg body weight) s.c. and ketamine HCl (100 mg/kg)/xylazine (10 mg/kg) i.p. Hair on the incision site was clipped, and the implantation area was disinfected by 5% iodine in 70% isopropanol. Antibiotics (100 μg/mL gentamycin) were sprayed on the area of incision to prevent infection, and skin was sutured using polypropylene suture. The total duration of the surgical procedure was around 5 min per mouse. Eighteen to twenty hours after pump implantation, a lethal dose of acetaminophen was administered i.p.
Phage Display. Peptide phage libraries, obtained from Dyax Corp., were selected for binding to biotinylated shFcRn, using three rounds of sequential pH 6 binding and pH 7.5 elution/amplification protocols. In each round, phages were incubated with biotinylated shFcRn for 30 min at room temperature in pH 6 binding buffer (50 mM MES, 150 mM NaCl, 0.1% Tween 20). After phage binding, streptavidin-coated magnetic microparticles (MG-SA; Seradyn) were added to bind the biotinylated shFcRn, and the microparticles were magnetically immobilized and washed with pH 6 binding buffer. Phage were eluted from FcRn/microparticles in pH 7.5 elution buffer (50 mM phosphate, 150 mM NaCl, 0.1% Tween 20) and were amplified between each round by infecting XL1 blue MRF' cells and collecting cells showing phage-encoded tetracycline resistance. In the first round, 100 pfu for each unique phage peptide in each of the TN-IV, TN-10-X, TN11-I, and TN12-1 libraries were pooled and added to the selection (1.4-3.0 × 10 11 pfu per library); for rounds 2 and 3, phage input was reduced to 10 11 pfu total per round. FcRn-binding phage was confirmed by phage ELISA as described previously (42) and was amplified by PCR using primers 3PCRUP (5′-CGGCGCAACTATCGGTATCAAGCTG-3′) and 3PCRDN (5′-CATGTACCGTA-ACACTGAGTTTCGTC-3′), the Core PCR System II (Promega), and a cycle consisting of 94°C for 5 min, 30× (94°C for 15 s, 55°C for 30 s, 72°C for 1 min), and 72°C for 7 min. Amplified PCR product was purified using the QIAquick PCR Prep Kit (Qiagen) and sequenced by the Tufts University Core Facility. Phage display identified a series of peptides, including SYN514 (Ac-AGVMHCFWDEEFKCDQGGTGGGK-CONH 2 ), which was shown by competition experiments not to block FcRn-albumin interactions (Table 2) . Peptide SYN514 was used during a second peptide phage screen before the addition of the phage to identify additional albumin-competitive sequences. This strategy uncovered the albumin-competitive peptide SYN571 and, through structure-activity relationships, the shorter sequence SYN1753 (Ac-RYFCTKWKHGWCEEVGT-CONH 2 ), which bound to shFcRn.
Statistical Analysis. Statistical analyses were performed using Prism (version 7.01; GraphPad Software, Inc.). Statistical significance (P values) was obtained using an unpaired t test (for comparisons between two groups), an ordinary one-way ANOVA (for comparisons between three or more groups), two-way ANOVA with Fisher's Least Significant Difference (LSD) post hoc test (for comparisons between three or more groups with two or more parameters tested), or a Mantel-Cox test (for comparisons of survival distributions). A two-sided P value less than 0.05 was considered significant.
